Dean W. Lim, M.D.

800-826-4673
Meet Medical Oncologist Dean W. Lim, M.D.
Medical Oncologist
Clinical Expertise
Head and Neck Oncology
Gastrointestinal Cancers
Research Area
Gastrointestinal and Head and Neck Cancers
Other Languages Spoken
Fookien
Mandarin
Tagalog
Appointments
Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Medical Oncology & Therapeutics Research
Research Teams
Developmental Cancer Therapeutics Program (CCC)
Gastrointestinal Cancers
Part of City of Hope's team since 1999, Dean W. Lim, M.D., says he still gets emotional when he's able to tell patients their cancer is in remission. “The patient will tear up. They're speechless. They're just happy. I feel like crying with the patient, too!”
 
Educated in the Philippines, Dr. Lim completed a fellowship in hematology/oncology at St. Luke's Roosevelt Hospital in New York City before arriving in California some 25 years ago. Well-versed in all aspects of oncology, he specializes in the treatment of head and neck cancer.
Location
Education & Experience
Board Certifications

  • 1989, Board Certified, Medical Oncology

  • 1985, Board Certified, Internal Medicine

Degrees

  • 1985-1987, Fellowship, Hematology/Oncology, St. Luke's Roosevelt Hospital, New York, NY

  • 1980, University of the East, Ramon Magsaysay Memorial Medical Center, Manila, Philippines

  • 1976, B.S., Premedicine, University of the East, Manila, Philippines

Fellowship

  • 1985-1987, Fellowship, Hematology/Oncology

Residency

  • 1982-1985, Residency, Internal Medicine

Professional Experience

  • 1999-present, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA

  • 2002-2003, Staff Physician, Riverside County Hospital, City of Hope Practice, Riverside, CA

  • 1999, Staff Physician, Huntington Memorial Hospital, Pasadena, CA

  • 1995-1999, Associate Oncologist/Hematologist, Private Practice, CareMore Medical Group, Brea, CA

  • 1990-1995, Staff Oncologist/Hematologist-Medical FHP Inc. HMO, Fountain Valley, CA

  • 1988-1995, Staff Internist Hospitalizing, FHP Primary Care M.D., Locum Tenens on Weekend FHP Clinics, Fountain Valley, CA

  • 1986-1987, Attending, St. Luke's Roosevelt Hospital Detox Unit, New York, NY

  • 1986-1987, ER Attending Cabrini Medical Center, New York, NY

Awards & Memberships
Memberships

  • American Society of Clinical Oncology

  • Southern California Academy of Clinical Oncology

  • Southwest Oncology Group

  • National Comprehensive Cancer Network for Antiemesis and Elderly Task Force

Publications
  • Lim D, Akman S, Margolin K, Carr BI, Leong L, Odujinrin O, Morgan RJ Jr., Doroshow JH. Phase I trial of synkayvite (Vitamin K3, Menadiol Diphosphate) in advanced malignancy. Invest. New Drugs 23: 235-239, 2005.
  • Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Kadhimi Z, Leong L, Lim D, Margolin K, Morgan RJ, Jr, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH. Feasibility study of concurrent infusional dexrazoxane and dose-intensive doxorubicin administered over 96 hours for the treatment of advanced malignancies. Cancer Chemother. Pharmacol. 54: 241-248, 2004.
  • Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, Shibata S, Chu P, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas J, Kogut N, Schriber J, Fermin E, Damon L, Doroshow JH. Prognostic indicators and survival in 120 patients with stage IIIB inflammatory breast carcinoma following dose-intense chemotherapy. J. Clin. Oncol. 22: 1839-1848, 2004.
  • Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res. 9: 461-467, 2004.
  • Shibata S, Frankel P, Leong L, Lim D, Margolin K, Morgan R, Somlo G, Synold T, Twardowski P, Doroshow JD. Phase I study of cisplatin (CDDP) in combination with ICRF-187 (ICRF) in the treatment of advanced malignancies. Proc. Amer. Soc. Clin. Oncol. 22: 164, 2003.
  • Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin KA, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. Phase I trial of intraperitoneal (ip) docetaxel (D) in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity (DLT) and pharmacokinetics (PK). Proc. Amer. Assoc. Cancer Res. 43: 551, #2741, 2002.
  • Doroshow JH, Margolin K, Chow W, Leong L, Lim D, McNamara M, Morgan R, Shibata S, Somlo G, Twardowski P, Weitzel J, Yen Y, Kogut N, Schriber J, Alvarnas J, Stalter S. High-dose chemotherapy with autologous stem cell rescue (PSCT) for relapsed nonseminomatous germ cell cancer (NSGCT): Effective salvage for poor-risk patients (pts) in first relapse. Proc. Amer. Soc. Clin. Oncol 21: 179a, # 714, 2002.
  • Newman EM, Longmate JA, Lenz H.-J, Carroll MI, Stalter SK, Lim D, Raschko JW, Shibata SI, Somlo G, Doroshow JH. Phase I and pharmacokinetic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine: a California Cancer Consortium study. Proc. Amer. Soc. Clin. Oncol. 21: 108a, #431, 2002.
  • Morgan R, Doroshow J, Synold T, Lim D, Shibata S, Margoln K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, PazB, Chu D, Frankel P. Phase I trial of intraperitoneal Iip) doecetaxel (D) in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Proc. Amer. Soc. Clin. Oncol. 20: 93b, 2001.
  • Shibata S, Chow W, Frankel P, Leong L, Lim D, Longmate J, Margolin K, McNamara M, Morgan R, Raschko J, Somlo G, Synold T, Tetef M, Twardowski P, Yen Y, Doroshow J, Lenz H, Gandara D. A phase I trial of oxaliplatin (OX) in combination with gemcitabine (G): A California Consortium Trial. Proc. Amer. Soc. Clin. Oncol. 20: 96a, 2001
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
Ratings
4.9
Show respect for what you say
4.8
Know important info medical history
4.8
Spend enough time with you
4.8
Provider listen carefully to you
4.7
Rate provider 0-10
4.7
Recommend this provider office
4.7
Provider explain in way you understand
Reviews
07/04/23
Good - Verified patient
07/04/23
Very very good - Verified patient
05/23/23
The oncologist team are always very supportive and attentive from day 1 to present, the compassion of this provider is beyond measure. We hope all providers are like him. The assigned nurse went above and beyond our expectations and has consistently shown care and support in every way she can. Couldn't ask for more. We are so blessed. Thank you City of Hope!!! - Verified patient
04/17/23
Provided my wife and I with clarity. - Verified patient
04/17/23
Best health care experience. Warm, personable, caring and understanding! - Verified patient